John G. Gribben

Research interests

Publications

• Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

  Blood · 2023 · https://doi.org/10.1182/blood.2023020578

• The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

  Blood · 2022 · https://doi.org/10.1182/blood.2022015851

• Genomic profiling for clinical decision making in lymphoid neoplasms

  Blood · 2022 · https://doi.org/10.1182/blood.2022015854

• Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.12.003

• AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.00010

• Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.00894

• Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30618-1

• Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma

  Cell · 2017 · https://doi.org/10.1016/j.cell.2017.09.027

• International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx097

• Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30097-3

• Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease

  JAMA · 2015 · https://doi.org/10.1001/jama.2015.16700

• Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma

  Nature Genetics · 2013 · https://doi.org/10.1038/ng.2856

• EZH2 mutations are frequent and represent an early event in follicular lymphoma

  Blood · 2013 · https://doi.org/10.1182/blood-2013-04-496893

• ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds517

• Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age

  Blood · 2005 · https://doi.org/10.1182/blood-2004-05-1947

• ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

  New England Journal of Medicine · 2004 · https://doi.org/10.1056/nejmoa040857

• Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation

  Science · 1993 · https://doi.org/10.1126/science.7694363

• Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.

  The Journal of Experimental Medicine · 1993 · https://doi.org/10.1084/jem.178.6.2185

Current projects

No projects listed.